Reviva Pharmaceuticals (NASDAQ:RVPH) Upgraded by Maxim Group to Buy Rating

Maxim Group upgraded shares of Reviva Pharmaceuticals (NASDAQ:RVPH) from a hold rating to a buy rating in a research report released on Friday,Benzinga reports. They currently have $7.00 target price on the stock.

Several other equities research analysts have also recently commented on the stock. Roth Mkm initiated coverage on shares of Reviva Pharmaceuticals in a research report on Friday. They set a “buy” rating and a $7.00 price target for the company. EF Hutton Acquisition Co. I upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 23rd. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $11.25.

Reviva Pharmaceuticals Stock Performance

Shares of RVPH opened at $1.88 on Friday. The business’s fifty day moving average price is $1.56 and its two-hundred day moving average price is $1.29. The firm has a market capitalization of $62.87 million, a price-to-earnings ratio of -1.69 and a beta of -0.12. Reviva Pharmaceuticals has a 52 week low of $0.60 and a 52 week high of $4.83.

Institutional Trading of Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC lifted its holdings in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 278,496 shares of the company’s stock after purchasing an additional 42,376 shares during the quarter. Geode Capital Management LLC owned about 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent SEC filing. Institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.